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In the past several years, we have taken advantage of a number of opportunities to advance the
intersection of next generation high-performance computing AI and big data technologies through
partnerships in precision medicine. Today we are in the throes of piecing together what is likely the
most unique convergence of medical data and computer technologies. But more deeply, we observe
that the traditional paradigm of computer simulation and prediction needs fundamental revision. This
is the time for a number of reasons. We will review what the drivers are, why now, how this has been
approached over the past several years, and where we are heading.
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1. Computing and Prediction
Prediction is part of our everyday lives. From early recorded predictions with deep societal
impact, such as the prediction of a solar eclipse by Thales of Miletus in 585 BC, to our daily
use of prediction in weather, tides, sports or science, the uses have become ubiquitous—although
the consequences of poor predictions are not all the same. Today we are turning to science-based
prediction to inform increasingly important problems. These are typically situations which cannot be
tested experimentally, from emergency preparedness or response, to safety and security in its many
dimensions. We have to protect against catastrophic events, things that cannot be instrumented or
measured beforehand, but that require enough understanding to invest limited resources optimally.
Our missions are the drivers of our technology needs. They include protecting the US energy sector
from man-made or natural disasters and ensuring that our nuclear deterrent will respond as needed.
Increasingly, though, we are turning to supercomputing as a tool that enable us to answer a new
and growing set of urgent questions. As we have developed our tools to meet this class of problems,
we find that, in addition to our direct responsibilities, our computing capabilities have led to us
becoming, in recent years, a “go-to” agency for informing urgent decisions. We are involved in a
regular cadence of events, including responses to Fukushima-Daiichi, the Gulf oil spill, Ebola, the
Christmas day “underwear” bomber, aviation security and so forth. Consequently, the certainty, or,
importantly, the quantified uncertainty, that we can provide with any set of complex predictions
underpins how we develop our next generation hardware and software tools.6
1 Oak Ridge National Laboratory, Oak Ridge, Tennessee, USA
2 Lawrence Livermore National Laboratory, Livermore, California, USA
3 US Department of Energy, Washington DC, USA
4Keynote Address, Supercomputing Frontiers Europe 2018, Warsaw. The views expressed in the article do not neces-
sarily represent the view of the U.S. Department of Energy or the United States.
5 Argonne National Laboratory, Argonne, Illinois, USA
6This manuscript has been in part authored by UT-Battelle, LLC, under contract DE-AC05-00OR22725 with the
U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for
ar
X
iv
:1
80
4.
11
00
2v
1 
 [c
s.A
I] 
 29
 A
pr
 20
18
Our tools for prediction are built around supercomputing simulations. Simulations can be sepa-
rated into two broad classes or approaches [10] which impact how we think about computer architec-
ture development. In the first and more conventional approach, the model is defined and driven by
a domain expert. Problems are well-defined and well-posed. Usually a mathematical theory exists,
a model can be stated explicitly, and much of our effort is spent on refining the numerical precision
of the solution. Researchers scale such “single-physics” calculations to the maximum scale the avail-
able computer can handle. The problems start with known degrees of freedom, perhaps defined in a
phase space or a Hilbert space, there are observables to measure, and the researcher usually already
lives in a discretized space, spending time controlling the accuracy of the numerical measurements
under investigation. It might be computing observables in lattice QCD, or free-energy surfaces, or
protein folding.
The second class are those which we are applying to high-leverage decisions; where the promise
of supercomputing is driving us to address complex, multifaceted issues of national importance,
but where the approach to prediction still requires significant mathematical development. These
questions are not necessarily well-posed and, in many cases, cannot be clearly stated in mathemat-
ical terms. They are often time-urgent, typically not asked by scientists but arising from events
where science needs to have a voice. There is usually no good starting point—no Hamiltonian or
Lagrangian, no observables to turn to, no well-defined phase space to start an analysis. Yet these are
the classes of questions that people care about. These are complex, multi-scale, multi-disciplinary
problems and can seldom be addressed by a single domain expert but rather require multidisci-
plinary teams of experts. Discovery also lies here, where we are limited by our imagination and the
risk we are willing to take.
It is this second class of problems that we will focus on here. In particular what prediction means
in this emerging problem domain and what it might take to strengthen our prediction capabilities.
When we are faced with critical events or crises, today we are likely to ask: Can simulation play a
role? This is not always the case, but if the answer is yes (noting that not everything is suited to
be scientifically-informed) we encounter immediate questions such as:
• What does it mean?
• What actions are needed and when?
• What is your confidence?
• What are the risks?
• What happened?
• Can it happen again?
We often do not know if we are asking the right questions or even the right people, or whether
we are positioned to answer them. Nevertheless, increasingly we are challenged to answer questions
such as these that drive our decisions and providing the best means to make them is the problem
at hand. In our work with this class of problems, we have built a discipline of capturing our best
mathematical sense of the overall uncertainty associated with the predictions, because there are
consequences to being wrong. We term this disciplined approach Uncertainty Quantification (UQ).
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It includes the ability to numerically verify the computational tools, to understand the dependence
of predictions on model uncertainties, and to experimentally validate predictions against available
relevant or adjacent data. There are many successes to date, and certainly significant money saved
in deferred costs. In all these cases, there is typically a cost for inaction as well.
2. Uncertainty Quantification is likely NP Hard
2.1. Limitations of Our Current Approach
In our 70 year-old approach to modeling physical systems, designed from the paradigm of von
Neumann architectures, UQ has developed as a mathematical afterthought. We usually start in a
space of discretized guiding equations and meshes, where a prescribed set of instructions defines
the time evolution of the problem at hand from initial to final time. We then add in a post-
hoc manner tools to accrue and capture overall uncertainty. These could be Bayesian approaches,
Monte Carlo or Latin hypercube sampling (LHS), running ensembles of calculations with different
models/parameters, and so forth. However, at the time of their introduction, these methods did
not anticipate the approaching richness of the numerics or experiments. This is illustrated in fig. 1
(a) where a UQ approach creates an overall cloud of predictions consistent with the ranges of
uncertainties in the model-based computational approach.
Figure 1. (a) Our current approach to UQ. Models make certain predictions after which we vary
assumptions, approaches, initial conditions etc to better capture the full cloud of predictions. (b)
In Machine Learning (ML) approaches, reduced dimensional manifolds are extracted from higher
dimensional data sets, with data incompleteness and noise, and learned models extracted. This
captures our post-Moore’s Law activities today. Here ‘UQ for ML’ needs to be developed to inform
uncertainties in learned models from the overall data. (c) The path we are taking to converge AI/ML
based learned models with model based predictions so that all numerical and experimental data can
help self-inform predictions, effectively building in UQ into a “cognitive predictive engine”.
We have led in the development of rigor in this field over the years, but today we argue that
the approach is dated and needs fundamental revision. Our historic approach is a systematic one
that involves comparisons between numerical simulations and experiments ranging in scale all the
way from full systems, down through subsystems, benchmark scales and unit scale problems [16].
Data is used to test all available length-scales of the simulations. When the richness of the simula-
tions exceeds that of the experiments, such ‘point-wise’ comparisons define a reasonable approach.
Today, with the increasing richness of data, already at peta-byte scales, we are plagued with the
challenge of trying to validate both spatial and temporal data against simulation data also at peta-
byte scales. The technology trajectory in sensors and detectors (leading to exquisite measurements
over many length and time scales) coupled with the advent of exascale computations will bring
both numerical and experimental data to exascales. Existing approaches to UQ and accompanying
computer architectures are not prepared for this. As we explore alternatives, we will need to retain
pragmatic solutions since we have missions to deliver; we need mathematical frameworks that are
implementable in practice.
To further add to the complexity, the extraction of physical models from data alone, in either
classical or quantum mechanical systems, is known to be NP-hard (see for example [2]). It is likely
the case that this approach to uncertainty quantification will fall into the same complexity class.
Herein lies the challenge—it is possible that our current approach to UQ for multi-scale simulations
is in fact intractable on today’s (von Neumann-based) technology path.
2.2. A Path Forward
Over the past three or so years, we have been examining how to make progress, building on
the advances in artificial intelligence (AI) and machine learning (ML) in particular. We know from
the study of games, such as Go, Chess or Poker, that heuristics can go quite far in pushing beyond
what traditional computation limits might have suggested. Machine Learning (ML) methods seek to
generate reduced dimensional manifolds from higher-dimensional data, generating effective models
from the data. This is illustrated in fig. 1 (b) where large data sets are aggregated, often incomplete
or noisy, and learned models are extracted. To provide a sense of the uncertainty in the learned
models created through this process, UQ for ML approaches need to be developed. Contrast this to
our traditional HPC approach to simulation which takes physical models, captured in discretized
forms, and provides a numerical cloud of predictions for given problems. We are seeking to approach
the (potentially) NP hard nature of UQ by finding a means to connect these two worlds, where the
ML-learned models are guided by the physical models, perhaps in the way heuristics can be used to
guide solutions to NP hard problems. We have been approaching this by trying to bring together
hardware and software technologies in areas as illustrated in fig. 2.
The challenges lie well beyond just hardware and software frameworks. Many machine learning
methods, such as deep neural networks, are not amenable to analysis of the propagation of uncer-
tainty. While training performance can be used to bracket effectiveness of an approach, there is
no current mathematical basis for UQ in ML that we can turn to. Consequently converging AI,
Big Data and HPC poses interesting mathematical challenges in terms of providing quantifiable
uncertainty in predictions. We are faced with the following dilemmas: There is too much data to
understand, let alone compare in its full richness to simulation today. UQ approaches are based on
our traditional computational paradigms, but in the age of ML and AI it has no firm mathemati-
cal foundation. Extraction of governing dynamical equations from any amount of data is provably
Figure 2. (Top) We are driving hardware and software convergence across three fields. (Bottom)
Some of the specific artificial intelligence (AI) class technologies we are exploring.
NP-hard [2]. Breaking away from the model of how we currently approach predictive simulation
on today’s computer architectures will require a leap of faith that is hard to do for those heavily
invested in our legacy tools, solvers and methods. However, breaking away from our current model
is likely the only way we will be able to effectively meet the demands of the future. This is illustrated
in fig. 1(c) where we are seeking both hardware and software means to create the union of data
and model informed predictions simultaneously so that UQ can be built into a new approach to
predictive simulation. Enter precision medicine.
3. Why Precision Medicine?
Precision medicine7 is an innovative approach intended to provide insight and inform physicians
on how to best tailor medical treatment plans, procedures, and therapies for individual patients by
taking into account the complexity of their specific health profile. It is a computationally-intensive
exercise enabled by the utilization of high performance computing capabilities and AI frameworks
and the integration of large-scale, diverse, complex layers of health and disease-related data such as
electronic health records (EHR), medical imaging, various -omics data (i.e. genomic, epigenomic,
phenomics, proteomic, metabolomics), basic sciences research, systems biology models, molecular,
pharmaceutical, and other biomedical related data [6, 8], illustrated in fig. 3. With AI, data gener-
ated from very large patient populations may be ‘learned’ into models that are then applied to the
individual patient or patient cohort, allowing prediction of what treatment, therapy, or prevention
strategy will work best. To make precision medicine work today, medical fields rely on methods
from statistics and computer science—mainly statistical models, machine learning, and data min-
ing. These statistics and machine learning models need comprehensive data products (-omics-based,
clinical history, laboratory results, lifestyle, environmental, etc.) which needs to be engineered with
consistency, precision, and quality.
7By precision medicine, we use the definition of Yamamoto: “Use a massive data network that aggregates and
analyzes information from huge patient cohorts, healthy populations, experimental organisms and reaches toward
disease mechanisms, and precision diagnosis and treatment for each individual.”
Figure 3. Precision medicine aims to integrate large-scale, diverse datasets reflecting the inherent
complexity of biological systems and their role in health or underlying disease.
We are challenged currently with a mistiming: the pressing questions that we have outlined
above have not yet reached a level where paradigm change is unavoidable. However, industry today
is making technology choices that are starting to define their architectural directions with respect
to ML and AI and the opportunities exist today for aligning these with the direction we would
like predictive simulation to evolve. To start to explore a transition in predictive simulations from
today’s paradigm to a possible future one, we have turned to a field that is replete with data but not
burdened by how we historically developed complex multi-scale predictive simulations. Our strategy
to attack this challenge is to seek large force multipliers by:
• Finding problems that can serve as attractors for new ideas, as a strategy to draw in broader
thinking and resources;
• Forcing the rethinking of traditional paradigms by challenging researchers with qualitatively
new classes of prediction through a richness of data;
• Increasing the number of people teaming together to find common solutions;
• Using the qualities of data to change how we think of many of our traditional approaches from
post Moore’s Law hybrid architectures to uncertainty quantification to codes.
Precision medicine provides a means to meet these goals. We have started by building around
three main elements: (a) Technology: Development and testing of next generation hardware and
software technologies; (b) Data: Aggregation of new sources of complex data, curated by experts
and restructured for large, high-end, scalable architectures; and (c) Partnerships: Buying down
risk through engaged partners who are driven by impacting outcomes in technology or precision
medicine. This includes other agencies, private sector, international partners and agencies, and
academia. In the next few sections we will outline some of these, with the overall intent of informing
our technology convergence challenge.
3.1. Joint Development of Advanced Computing Solutions for Cancer
“JDACS4C”
In mid-2015 we launched a partnership with the National Cancer Institute (NCI) that has five
efforts that define it: i. molecular level understanding, ii. patient health trajectories, iii. population-
level studies, and two crosscutting efforts that include UQ and a cancer distributed learning envi-
ronment project called CANDLE. These projects involve four of our national laboratories (Argonne,
Livermore, Los Alamos and Oak Ridge), the NCI’s Frederick National Laboratory, as well as NCI
scientists. Data sources are provided by the NCI, and we focus on using the NCI challenges to
develop new technologies which can be used to advance both agency’s missions.
At the molecular level, we are examining the biology of oncogenic RAS proteins in lipid mem-
branes. RAS-based cancers are the most intractable challenge in oncology today, defeating our best
technologies. Mutated RAS is responsible for 93% of all pancreatic cancers, 42% of all colorectal
cancers, 33% of all lung cancers, with over 1 million deaths worldwide and no effective inhibitors.
The mechanisms of RAS activation are not well understood, hindering the discovery of effective
therapeutics. We are developing a hybrid AI/HPC molecular-scale methodology for RAS activation
to help model development of targeted therapies for RAS-based cancers. Our approach is highlighted
in fig. 4. New validation experiments coupled to atomistic and coarse-grained molecular dynamics
Figure 4. The schematic approach of the RAS-based cancer effort is shown here.
simulations are being used to dynamically model the behavior of RAS complex in the context of
a complex membrane. Experiments incorporate advanced imaging and interaction data from such
sources as cryo-EM, NMR, crystallography and neutron sources will focus on membrane-bound RAS,
mutated RAS and RAS complexes will be used in conjunction with simulation to build accurate
interaction parameters that will in turn power hyper-scaled simulation that access, for the first time,
biologically relevant length and time scales for this problem. To date, we have demonstrated a novel
multi-scale methodology linking atomistic and continuum resolution simulations, briefly captured
in fig. 5. This includes hyper parameter optimizations to characterize sub-states from molecular dy-
namics simulations, and machine learning on-the-fly during the running code to optimize parameter
exploration. By scaling this capability to next-generation supercomputing technology, we aim to
capture the behavior of RAS and mutated RAS molecules and complex interactions at the cellular
membrane.
At the cellular level, we are developing AI as a means to improve treatments. Quantitatively
predictive models for cancer therapy could one day support the treatment choices a physician and
patient make toward achieving the best possible clinical outcome. To fulfill this vision, we need to be
able to predict accurately the efficacy of cancer drugs in model systems. To that end, we are building
scalable models that integrate data derived from pre-clinical studies from cell lines, organoids, and
patient-derived models (see fig. 6). This framework accounts for and quantifies uncertainties in the
Figure 5. An example of macro to micro scale coupling with multiple lipid layers (left) at the cell
membrane shown and RAS moving on the surface. Note the impacts are felt inside the cell. (right)
Micro states are captured through hybrid AI methods that can draw in atomistic level dynamics
and time scales.
state of systems of interest and takes advantage of information available in different forms and scales.
Using machine learning we construct integrated models that include molecular characterization of
the tumors, drug descriptors and drug fingerprints as well as information about dose and types
of experiments. The resulting family of learned models can predict drug response of tumors for
standard of care drugs, drug combinations as well as drugs under development. Our approach
outlined in fig. 7, addresses questions such as: Which molecular features or combination of features
are most predictive of drug response? How best to represent and quantify uncertainty in the
predictions of the models? Given the model prediction landscape that includes biological response
and estimates of certainty what is the best course of action to validate the predictions and improve
the models?
Figure 6. Patient Derived Xenograft Models: Tumors obtained from patients are grown in NSG
mice to model drug response.
We are constructing deep learning models from the response and feature sets of cell lines and
PDX data that can be trained on integrated datasets from many experiments. These training data
include data from multiple labs, over a thousand cell lines, tens of thousands of compounds and
thousands of drug combinations. We are developing methods to interpret the resulting models to
extract the most predictive features. Existing training datasets are often unbalanced with some
cancer types underrepresented and with response data often skewed. To address these issues we are
developing methods to augment our training data using generative adversarial networks (GANs).
GANs have been widely used in machine learning community and represent one of most innova-
tive developments in representational learning of the past decade. We are the first group to apply
these methods to the Cancer drug response problem. To address uncertainty we have adopted the
”dropout” method of training our networks with dropout and then increasing the dropout fraction
for inference. This approach has been shown to be equivalent to a Bayesian approximation. The
resulting models when run in inference mode are effectively sampling from a distribution of models
and as a result we can estimate the uncertainty in the predictions. From this uncertainty estimate
we can visualize the response landscape to gain some insight to where the model is relatively more
or less confident. Using this landscape we can identify needed experiments (or additional training
data) that would reduce the uncertainty.
Figure 7. The schematic approach to the pre-clinical screening effort is shown here.
At the population level, we are working to learn from individual cancer patients and build on the
participation of cancer patients in understanding response to therapy, quality of life and outcomes
at a national level. This project uses the existing SEER [20] cancer registries and tumor registries as
a hub for reporting therapeutic, genetic and genomic information across the United States. Building
a strong, population-wide evidence base of cancer diagnosis, treatment, and outcomes information
is critical for process improvement and modeling the cancer patient experience. Providing a hub for
patients and providers to share information is critical to in silico modeling of cancer at a population
level. A population-based understanding of cancer presentation, treatment and outcomes will in
turn be critical to realizing the potential of cancer precision medicine. This project explores novel
mechanisms for data sharing, consent, direct patient participation in research, and the impact of
variations in care practices. Increasingly available information on patient treatment response will be
increasingly integrated providing insight critical into evaluating and understanding the effectiveness
of cancer treatment choices. The approach is sketched in fig. 8.
Figure 8. The Surveillance Perspective: Improve the effectiveness of cancer treatment in the “real
world” through computing
We are developing algorithms and related informatics tools needed to automatically capture, in-
tegrate, analyze, and effectively utilize the information needed to support a comprehensive, scalable,
and cost-effective national cancer surveillance program. Since critical amount of patient information
is contained in unstructured clinical text such as pathology and radiology reports, initial efforts are
focused on developing, benchmarking, and deploying across cancer registries advanced text com-
prehension algorithms to automatically and reliably abstract important patient information from
cancer pathology reports [4, 18, 22]. By collecting, linking, and analyzing additional heterogeneous
data (such as pharmacy data, claims, biomarkers) we can generate a richer profile for the cancer
patients, including healthcare delivery system parameters and continuity of care. These patient
profiles will enable data-driven modeling and simulation patient-specific health trajectories laying
foundation for in silico, large-scale evaluation of precision cancer therapies. Overall, these linked
efforts provide the data infrastructure and methods to support precision oncology research at the
population level.
Beyond these three scales of focus, there are two cross-cutting activities. For UQ, the com-
putation required includes high-dimensional, non-convex, optimization, machine learning and deep
learning, large-scale, long-time molecular dynamics, modeling strongly nonlinear stochastic systems,
and carefully quantifying uncertainty in predictions. In addition, we are working in CANDLE to
thoughtfully integrate machine learning methods with mechanistic modeling and to fully exploit
the biological knowledge of molecular interaction networks in designing informative experiments.
This exascale deep learning environment builds on existing open source deep learning frameworks
through a software stack that includes workflow, scripting, execution engine and optimization. The
effort pushes the envelope in rapid data integration methods that combine a variety of molecular
level assays with imaging and phenotype assays to produce an integrated “feature space” that will
underpin the basis for development of predictive models.
3.2. AI and Precision Diagnostics – Traumatic Brain Injury (TBI)
Traumatic Brain Injury (TBI) is an area of clinical research perfectly poised in the second
class of problems. The problem space for TBI is less well defined in that there are severe defi-
ciencies in both the mechanistic understanding of TBI and currently crude clinical classification
or diagnostic delineation of severity. Recently, understanding the cellular mechanisms of TBI has
improved; however, given the broad classification of TBI diagnosis, this has limited translation into
clinical relevance. The current TBI classification schema is dependent on a relatively insensitive and
symptom-based approach [13], preventing any mechanistic advancements to manifest into real-world
application. Given that TBI is often disabling and an exponentially increasing source of morbid-
ity and mortality in older adults [7], improving understanding and developing mechanistic basis of
treatment approaches would have a profound impact.
We are starting an effort to access, host and analyze a super-dataset by integrating several
large and discordant datasets related to TBI. These data include a rich mixture of x-ray and MRI
brain images, measurements of biochemical markers in the blood, and clinical data on symptoms
and outcomes. Today, physicians have limited capability to bring these data together to provide the
best possible diagnosis and treatment for individual patients. We believe cognitive computing could
provide improved diagnosis and treatment. The Transforming Research and Clinical Knowledge in
Traumatic Brain Injury (TRACK-TBI) dataset [23] is one of the most detailed ever collected in
neuroscience and provides an opportunity to demonstrate the feasibility and utility of this approach.
Additional public and private datasets are also being considered to expand the depth, richness, and
complexity of the data. In the initial steps, using large-scale computing and machine learning, we
are working on precision diagnostics for subjects in the TRACK-TBI study. These insights will
be validated and verified by University of California, San Francisco medical school collaborators.
Precision diagnosis represents a key frontier for making data-driven decisions in complex, uncertain,
and discordant data environments. Longer term, the data analytic concepts developed here will work
together with the other data sets outlined in this paper and could be important in the context of
broader set of high-significance illnesses. By making TBI diagnosis more sensitive and accurate by
reducing the time for MRI-based connectome analysis from a day to a few seconds creating a Real-
Time Connectome (RTC). Initial efforts have demonstrated a factor of 1000 speedup in analysis.
The tools are intended to provide physicians accessible tools to predict a TBI patients trajectory
and optimize their treatment based on real-time analysis of clinical inputs, brain images, genomic
data, and biomarkers. Already AI tools and massive parallelization for TBI data have initiated the
development of precision TBI phenotypes to improve our current classification system.
3.3. Characterization and Understanding of Complex Diseases – Big Data
Science Initiative (BDSI) with the Department of Veterans Affairs (VA)
In early 2016 we started a partnership with the Department of Veterans Affairs (VA), which we
call MVP-CHAMPION (Computational Health Analytics for Medical Precision to Improve Out-
comes Now). As the program has grown both in data and vision, it has grown into a Big Data Science
Initiative (BDSI). The aims of the program are to improve the health and well-being of the veterans,
and the population as a whole, through better understanding of underlying causes of diseases and
conditions, hereditary factors and health history while driving AI, high-performance computing,
and data science convergence. We are focusing on studying underlying hereditary, lifestyle, and
demographic factors of the diseases such as prostate and liver cancer, clinical depression (leading to
suicide), and heart disease. The program uses two of the largest health data assets, in the US and
in the world, respectively – Million Veterans Program (MVP) genomic databank [5], which is one
of the largest global genomic datasets, and VA’s Corporate Data Warehouse (CDW) [1, 17], which
houses the health data of more than 22 million veterans, and is one of the most complete health
datasets. CDW is the primary source for all business intelligence, analytics, and health services
research in the VA. As of 2016, it was storing data for some 22 million patients including 7.7 billion
lab results, 4.5 billion clinical orders, 3.2 billion clinical notes, 1.4 billion appointments, 2.4 billion
encounters, 1.4 million surgeries, 1.3 oncological treatments, 202 million radiology procedures, 71
million immunizations, 2.2 billion pharmacy files, 2.2 billion health factors, 3.3 billion vital signs,
17 million admissions, and 315 million consults.
Figure 9. Heterogeneous data is translated into computing-optimized structures that serve as a
foundation for downstream analytic and AI processing aimed at diseases characterization and un-
derstanding.
The richness of the data (fig. 9) and the complexities of the challenges faced by the VA have cre-
ated partnerships that drive both next generation technologies and our path to fig. 1 (c) and advance
VA precision medicine priorities. The topics include future high-impact opportunities, crosscutting
technologies, and can be summarized as follows:
Markedly enhanced prediction and diagnosis of Cardiovascular Disease (CVD) CVD is the leading
cause of death in US men and women including Veterans and the cost of care for CVD conditions
is high. A collaborative CVD project would build predictive tools that (1) identify improved sets
of risk factors for specific types of CVD, and (2) develop methods to inform individualized drug
therapies to prevent, preempt and treat CVD. The new tools will enhance prediction, diagnosis and
management of major CVD subtypes in Veterans.
Precision discrimination of lethal from non-lethal Prostate Cancer Many prostate cancer patients
undergo surgery or other treatments with significant side effects without knowing whether the risk
of such treatments outweigh the benefits, since a priori data are limited for many patients regarding
lethality. The collaborative prostate cancer project will build improved classifiers for prostate cancer
that may significantly aid health care providers in distinguishing lethal from non-lethal prostate
cancers. Reducing unnecessary treatments will provide an increased quality of life for patients and
allow VA to focus resources where most effective.
Patient-specific analysis for Suicide Prevention Suicide is the 10th leading cause of death in the US,
and is significantly higher in the Veteran population, accounting for 20-22 deaths per day [12]. Efforts
would improve identification of patients at risk for suicide through new patient-specific algorithms
built to provide tailored and dynamic suicide risk scores for each veteran at risk. Working closely
with VAs Office of Suicide Prevention, the tools would be used to create a clinical decision support
system that assists VA clinicians in suicide prevention efforts, and helps to evaluate effectiveness of
various prevention strategies.
Crosscutting Advances in methods and technology Cutting across the three projects are analytic
methods that can be scaled to apply to research using the VA EHR and MVP data, as well as
requirements for next generation AI and BD analytics. The crosscutting methods include advanced
methods in genomic imputation to harness genotype and sequence data in MVP; phenome-wide
association studies (PheWAS) [3], and methods in pharmacogenetics [21] analysis. The analytics
requirements push development of DOE technologies in key areas including large-scale data analyt-
ics, computer modeling, large-scale machine learning, information extraction, and natural language
processing as well as algorithms for cost-sensitive decision making under uncertainty. Success in
developing these enabling technologies will have large impacts on DOE missions including science,
energy, and national security.
In addition to these efforts, there are additional future high impact opportunities. This in-
cludes: Predict and control effects of multiple drugs: polypharmacy, defined as use of five or more
medications at a time, may be our countrys number one drug problem, and it is associated with
non-adherence, adverse drug events, falls, inappropriate prescribing, hospitalization, and mortal-
ity [19]; Computer interpretable clinical notes: An estimated 80% of all electronic medical record
information is stored only in unstructured data [15], including clinical notes by healthcare providers
and clinical reports. Here natural language processing (NLP) and information extraction (IE) tech-
nologies are being developed to extract information from unstructured (medical) records, allowing it
to be combined with other medical data to accelerate understanding and improve patient outcomes;
Knowledge enabling classifiers for disease: Disease is often grouped into general categories that de-
fine a constellation of symptoms, the organ system affected, or some other outward manifestation.
3.4. AI/HPC-based Drug Discovery – Accelerating Therapeutics for
Opportunities in Medicine (ATOM) Partnership
The process of drug discovery, as currently in place, is a long, and costly process, and with
a high rate of failure [14]. Research questions in this often revolve around the question if there is
a better way to rapidly get new medicines to patients. Even before human trials begin, we know
that the pre-clinical discovery phase of drug development takes an average of 5.5 years, and absorbs
33 percent of total developmental cost of medicine development. Millions of compounds get tested,
thousands are made, and most fail. The phase space of potential small molecule drug candidates
is huge - on the order of 1060 potential molecules - making the exhaustive, traditional discovery
process almost impossible. Consequently, judicious choices in navigating this complex design space
must be made. Clinical success rates are still only 12%, indicating poor translation to human
patients. There is a critical need to accelerate the development of more effective therapies, and to
make the process more efficient. To this end, we are partnering with a pharmaceutical & technology
companies, medical research laboratories and institutes to develop a new, computationally enabled
starting point – transforming drug discovery from a slow, sequential, and high-failure process into
a rapid, integrated, and patient-centric model driven by high-performance computing. The ATOM
partnership between GlaxoSmithKline, the NCI, DOE, and UC San Francisco - now expanding to
include new partners - aims to integrate shared access to previously unused pharmacy data sets, the
unique AI/HPC/BD technologies, and new approaches to characterize biology to implement new
ways to get medicines to patients, going from target to first in human experimental trials in twelve
months or less. The initial efforts are cancer-focused.
ATOM utilizes a laboratory composed of leading technologies, physiologically relevant complex
biological models, and pre-competitive data from GSK on millions of compounds that have been
biologically evaluated with access to trillions of compounds in their libraries. It combines the global
research and development leadership of the parent organizations with the agile innovative culture
of a startup to bring new medicines to the patient. It enables access to new models generated
through machine learning, simulation and experiments including the validation of experiments that
would accelerate pharmaceutical candidate identification from one year to a few months; and it
promotes interdisciplinary work with nontraditional partners and increased interactions between
communities that may not often intersect, for example, biochemists, biologists, chemists, molecular
biologists, computational scientists, infectious diseases specialists, computing engineers, and the
oncology community.
Figure 10. Accelerating Therapeutics for Opportunities in Medicine (ATOM)
3.5. International: US-Norway Partnership and Cancer Risk Factors
The Cancer Registry of Norway (CRN) [11] is the oldest, and one of the most complete can-
cer registries in the world, sourced from the single-payer healthcare system, and from the well-
understood population. The partnership with CRN provides an opportunity for us to test tools
on this unique data asset. The initial efforts are focused on predictive models of cervical cancer
screening sequences with attention on optimization of testing frequency. It uses patient question-
naires and HPV status as covariates. The collaboration is currently advancing from 100,000 to over
one million cases. There is an ongoing discussions with other Nordic countries about joining efforts
to co-develop tools and to co-locate researchers. The initial effort, jointly with the Oslo Cancer
Cluster [9], considers a database of 1,728,336 unique Norwegian womens cervical cancer screening
results with multiple screening results are recorded over time for each patient. The data covers a
25-year period, 1991 − 2015, with screening times unique to each patient. Overall, there are over
ten million individual records.
Figure 11. We are using precision medicine data as an accelerator for next generation technologies
in high performance computing
4. Summary
The demands of UQ in computer prediction, a problem we believe to be NP-Hard, cannot be
met on our current HPC technology path. We see that cognitive computing, defined through the
technology convergence of AI, Big Data and HPC is an essential next step. With vendor technology
decisions being made now and in the next few years in AI and HPC, it is urgent that broad classes
of HW and SW are explored to best leverage commercial technology roadmaps. To that end, we are
using precision medicine data as a force multiplier and accelerator. This rich, complex, unstructured,
heterogeneous, curated, massive data is likely the richest class of data to work on today and brings
with it unique partnerships that buys down risk in exploring the many splintered paths forward each
with their own tough challenges and also shares costs. We are using this to inform architectures that
can integrate neuromorphic processors, GPGPUs, FPGAs, spiking neurons, or other innovations
into HPC so we can reach the type of convergence discussed in Section 2 and fig. 1 as part of HW/SW
path forward. It is also a problem set that provides a clean-slate: it is not burdened by how we
believe we should solve the problem. We are already modifying our path to next generation exascale
systems based on the work outlined above. We will need not only advancements in mathematical
frameworks for UQ that work with AI and ML, but we will need to understand how we bring together
learned models with predictive models into a common framework. As we build new architectures,
technologies and tools based on the complexity of the data, we have an opportunity to push the
frontier of precision medicine and next generation high-performance computing simultaneously.
New ideas and broadening the conversations and partnerships are welcome and an important part
of making any progress.
This paper is distributed under the terms of the Creative Commons Attribution-Non Commercial
3.0 License which permits non-commercial use, reproduction and distribution of the work without
further permission provided the original work is properly cited.
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